TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females 18-65 years old~* VEINES Sym Score less than 75 points~* Varicose Vein clinical classification CEAP 2, 3, 4, or 5~* Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein~* Superficial venous disease manifested by both symptoms and visible varicosities~* Ability to comprehend and sign an informed consent document and completed study questionnaires in English~Exclusion Criteria:~* Incompetence of the SSV which substantially contributes to the filling of visible varicose veins~* Current or previous Deep Vein Thrombosis~* Leg obesity~* Peripheral arterial disease in the leg to be treated~* Reduced mobility~* Planned prolonged travel with limited mobility with in 4 weeks of treatment~* History of pulmonary embolism or stroke~* Major surgery, prolonged hospitalization or pregnancy within 3 months~* Current anticoagulation therapy (within 7 days of enrollment)~* Participation in a clinical study involving a investigational product within 3 months~* Major co-existing disease or clinically significant laboratory abnormalities~* Known allergic response to polidocanol or heparin or severe and/or multiple allergic reactions~* Women of childbearing potential not using effective contraception one month prior to enrollment and/or unwilling to continue while on study~* Pregnant or lactating women~* Current alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Varisolve (polidocanol endovenous mircofoam)
- 2 (Type: PLACEBO_COMPARATOR): Agitated saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First Line Osimertinib in the Real World: an Inter-regional Prospective Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histological confirmed diagnosis of NSCLC and EGFR mutation in exon 18-21;~* locally advanced inoperable or metastatic disease (stage III and IV according to 8th edition of the TNM classification for lung cancer);~* first line treatment with the third generation EGFR TKI, osimertinib;~* age \>18 years~* written informed consent~Exclusion Criteria:~Patients who receive study drugs in clinical trials will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Untreated EGFR-mutant advanced non-small-cell lung cancer patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 20-65 years;~2. Hypertension with average 24-hour BP of \>130 mmHg systolic or \>80 mmHg diastolic in spite of treatment with one medication;~3. Office systolic blood pressure \>140 mmHg and less than 180mmHg;~4. Able to comprehend and sign the consent form;~5. Able to tolerate either hydrochlorothiazide 25 mg or amlodipine 5 mg daily for 3 weeks during the run-in phase.~Exclusion Criteria:~1. Diagnosis of secondary hypertension;~2. Hypertension with systolic BP \>180 mmHg in spite of 1 medication;~3. Chronic heart failure requiring diuretics, Angina or coronary syndrome requiring anti-angina therapy with CCB or beta blockers, or more than 0.4 mg/hr nitroglycerine patch;~4. Left Ventricular Ejection Fraction (LVEF) \<20% or LV end systolic dimension \>75 mm;~5. Significant valvular disease such as; more than mild disease of aortic or mitral valve;~6. Technically sub-optimal acoustic window or regional wall motion abnormalities;~7. Patients currently on both CCB and diuretics for more than 4 weeks;~8. Normal 24 hour ABPM at the end of the run-in period;~9. Physical handicap that precludes adequate performance of 6-minute walk such as arthritis;~10. Concomitant comorbidity that might compromise ability to evaluate treatment or enhance risks of therapy, such as: atrial fibrillation with resting ventricular rate of \>100 bpm; morbid obesity; uncontrolled diabetes mellitus; severe chronic obstructive pulmonary disease (COPD); hypertrophic cardiomyopathy; and documented history of non-compliance with treatment;~11. Any condition or disorder other than hypertension that: Requires prolonged hospitalization; May limit life expectancy within 2 years; would increase the risk of participation to the subject (in the opinion of the investigator).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Diuretic-Based Hypertension Therapy
- 2 (Type: ACTIVE_COMPARATOR): Non-Diuretic-Based Hypertension Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measurements of Angulation of the C-spine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Persons aged 18yrs and over to those aged 30yrs~2. Persons aged 70yrs and over~3. Ability to give informed consent to participate in the study~Exclusion Criteria:~1. Persons under 18yrs of age and those aged 31yrs -69yrs~2. Persons who lack capacity to consent for entry into the study~3. Persons who are unable to complete the visual analogue score or questionnaire due to co-existent visual and hearing loss. Severe hearing impairment will be defined as unable to hear the researcher with hearing aids if required. Severe visual impairment will be defined as being unable to read the patient information sheet even with visual aids.~4. Persons unable to understand the information leaflet in English.~5. Those with current neck pain, known previous C-spine injury or known medical condition affecting the spine.~6. Persons who do not pass the safety questionnaire to undergo an MRI scan~7. Persons who are unable to tolerate an MRI scan due to claustrophobia~8. Persons who are unable to transfer to the scanner table independently~9. Persons unable to lie flat and still for 10 minutes~10. Persons who do not give consent to their General Practitioner being informed of scan results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Spinal collar (Type: OTHER): Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* eGFR \> 60 mL/min/1.73 mq (for the patients without renal failure)~* eGFR 10-60 mL/min/1.73 mq (for the patients with renal failure)~Exclusion Criteria:~* Type 1 diabetes~* Hypersensitivity to Linagliptin or excipients~* Intolerance to other DPP-4 inhibitors~* Terminal renal failure (eGFR \< 10 mL/min/1.73 mq)~* Use of GLP-1 analogs or other DPP-4 inhibitors~* Recent (within 1 month) trauma or surgery or acute diseases~* Any acute or chronic inflammatory condition~* Immunosuppression or organ transplantation~* Pregnancy or lactation~* Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): Linagliptin 5 mg tablets daily for 4 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets 1 daily for 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hypertensive patients with diabetes mellitus~* Hypertensive patients~* Hypertensive patients with renal disease~Exclusion Criteria:~* Cardiac, hematologic or hepatic disease~* Renal insufficiency (serum creatinine values\> 2 mg/L)~* Hormone-induced hypertension~* Cerebral infarction or hemorrhage~* Other major diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment resistant depression requiring outpatient ECT~* Planned right unilateral ECT stimulation~* English speaking~* Able to provide written informed consent~Exclusion Criteria:~* Known brain lesion or neurological illness that causes cognitive impairment~* Schizophrenia~* Schizoaffective disorder~* Blindness or deafness or motor impediments that may impair performance for cognitive testing battery~* Inadequate ECT seizure duration with etomidate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Etomidate + ECT (Type: ACTIVE_COMPARATOR): General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
- Ketamine + ECT (Type: EXPERIMENTAL): General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
- Ketamine alone (Type: SHAM_COMPARATOR): General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Participant has provided informed consent~* History of migraine (with or without aura) for ≥ 12 months before screening~* ≥ 4 migraine days per month on average across the 3 months prior to screening~* Treatment with 1 oral migraine preventive medication and/or concomitant use of OnabotulinumtoxinA injections for migraine prevention.~* Participant reports to their provider intolerance or insufficient response with their current preventative treatment~Exclusion Criteria:~* History of cluster headache or hemiplegic migraine headache~* Unable to differentiate migraine from other headaches~* Evidence of substance-related disorders~* Active chronic pain syndromes (eg, fibromyalgia and chronic pelvic pain)~* No therapeutic response with \> 3 migraine preventive medication categories~* Used a prohibited medication, device, or procedure~* Other clinically significant disorder, condition, or disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have a diagnosis of idiopathic Parkinson's disease (PD) according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria~* Demonstrate persistent motor fluctuations in spite of individually optimized treatment~* Subject must experience a minimum of 3 hours Off time~Exclusion Criteria:~* Subject's PD diagnosis is unclear or there is a suspicion that the subject has a Parkinsonian syndrome such as secondary Parkinsonism (e.g., caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinson-plus syndrome (e.g., Multiple System Atrophy, Progressive Supranuclear Palsy, Diffuse Lewy Body Disease, Corticobasilar Degeneration), or other neurodegenerative disease that might mimic the symptoms of PD.~* Subject has undergone neurosurgery for the treatment of Parkinson's disease~* Subject for whom the placement of a PEG-J tube for LCIG treatment is contraindicated or is considered a high risk for the PEG-J procedure according to the gastroenterology evaluation (e.g., pathological changes of the gastric wall, inability to bring the gastric wall and abdominal wall together, blood coagulation disorders, peritonitis, acute pancreatitis, paralytic ileus).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levodopa-Carbidopa Intestinal Gel (Type: EXPERIMENTAL): Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.~Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have given informed consent~* Patients after primary percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI)~* Men or women with no child bearing potential~* Onset of symptoms to balloon time \< 6 hours~* ST-elevation of at least 2 mm in at least 3 leads on 12-lead electrocardiogram (ECG)~* Primary PCI indicated per standard of care~* First myocardial infarction (MI)~* Single index lesion with complete occlusion \[thrombolysis in myocardial infarction (TIMI) flow 0/I\] of one target vessel.~Exclusion Criteria:~* History of MI (from patient history, or from ECG)~* Chest pain or other angina symptoms in the 24 hours before the first recognized symptoms of the acute myocardial infarction (AMI)~* Need for coronary artery bypass graft (CABG)~* Administration of any thrombolytic agent since onset of AMI symptoms~* Serious procedural complications (e.g., procedural unintended occlusion of coronary artery branch, cardiac tamponade, emergency bypass operation, LM dissection, etc.)~* Presence of cardiogenic shock: hemodynamically unstable and/or need for positive inotropic agents~* Contraindication to cardiovascular magnetic resonance (CMR): claustrophobia, pacemakers, defibrillators and other electronic devices, and metallic cerebral clips; frequent extrasystoles (\> 12/Min) or atrial fibrillation (AF).~* Known renal dysfunction defined as serum creatinine \> 250 µmol/l~* Previous CABG~* History of congestive heart failure (CHF)~* Body mass index (BMI) \> 35~* Patients who cannot communicate reliably with the investigator~* Patients who are unlikely to cooperate with the requirements of the study~* Patients who are unwilling and/or unable to give informed consent~* Patients at increased risk of death from a pre-existing concurrent illness~* Patients participating in another clinical study~* Patients who have used any other investigational drugs within 1 month of first dosing~* Patients who have participated already in this study~* Patients who are employees at the investigational site; relatives or spouse of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 400 mg injected in 2 divided boluses
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Peripheral T-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time \> 3 months Histological confirmed Peripheral T cell lymphoma None of chemotherapy or radiotherapy has been previously used None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal (Inclusion Criteria of 1,3,6 groups ) At least one measurable lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test of women at reproductive age must be negative Patients could be followed up None of other relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments.~volunteers who signed informed consent.~Exclusion Criteria:~Disagreement on blood sample collection Patients allergic of any of drug in this regimen or with metabolic disorder Pregnant or lactating women Serious medical illness likely to interfere with participation Serious infection Primitive or secondary tumors of central nervous system Chemotherapy or radiotherapy contraindication The evidence of CNS metastasis History of peripheral nervous disorder or dysphrenia patients participating in other clinical trials patients taking other antitumor drugs patients estimated to be unsuitable by investigato

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GDPT regimen (Type: EXPERIMENTAL): GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
- CHOP regimen (Type: EXPERIMENTAL): CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written, signed, and dated informed subject/parent consent; and for subjects who are minors, age-appropriate assent (performed according to local regulations).~* Males or females at least 4 years of age.~* No flare-up symptoms within the past 4 weeks, including at the time of enrollment.~* Abstinent or using two highly effective forms of birth control.~* Accessible for treatment and follow-up; able to undergo all study procedures including low-dose WBCT (excluding head) without sedation.~Key Exclusion Criteria:~* Weight \<10 kg.~* Concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib.~* Amylase or lipase \>2x above the upper limit of normal (ULN) or with a history of chronic pancreatitis.~* Elevated aspartate aminotransferase or alanine aminotransferase \>2.5x ULN.~* Fasting triglycerides \>400 mg/dL with or without therapy.~* Female subjects who are breastfeeding.~* Subjects with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.~* Simultaneous participation in another clinical research study (other than palovarotene studies) within 4 weeks prior to Screening; or within five half-lives of the investigational agent, whichever is longer.~* Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palovarotene Chronic/Flare-Up Regimen (Type: EXPERIMENTAL): Participants received 5 mg palovarotene once daily for up to 48 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete